iSpecimen Inc. (NASDAQ:ISPC – Get Free Report) saw a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 112,840 shares, a growth of 119.2% from the April 30th total of 51,489 shares. Currently, 8.9% of the shares of the company are sold short. Based on an average daily volume of 1,080,390 shares, the days-to-cover ratio is currently 0.1 days.
iSpecimen Stock Performance
ISPC stock traded down $0.27 during midday trading on Tuesday, reaching $3.07. 82,620 shares of the company’s stock traded hands, compared to its average volume of 321,507. The company has a 50-day moving average price of $5.01 and a two-hundred day moving average price of $11.06. iSpecimen has a 52 week low of $3.10 and a 52 week high of $127.20. The firm has a market capitalization of $4.42 million, a PE ratio of -0.05 and a beta of 1.62.
iSpecimen (NASDAQ:ISPC – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($6.66) earnings per share (EPS) for the quarter. iSpecimen had a negative net margin of 1,080.16% and a negative return on equity of 584.65%. The business had revenue of $0.16 million for the quarter.
Wall Street Analyst Weigh In
View Our Latest Research Report on iSpecimen
Institutional Investors Weigh In On iSpecimen
An institutional investor recently bought a new position in iSpecimen stock. Virtu Financial LLC bought a new stake in shares of iSpecimen Inc. (NASDAQ:ISPC – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned 0.65% of iSpecimen at the end of the most recent reporting period. 13.62% of the stock is owned by institutional investors and hedge funds.
iSpecimen Company Profile
iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.
Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.
Read More
- Five stocks we like better than iSpecimen
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.
